Boston-based Vertex Pharmaceuticals failed to reach its clinical goals for its type 1 diabetes treatment, VX-264, leading to the discontinuation of the program. The effort focused on replacing lost insulin production with islet cells derived from donor stem cells, avoiding the typical need for chronic immunosuppression in cell therapy. However, the failure doesn’t rule out the use of the therapy’s cells (zimislecel) in another form, which is currently in Phase 3 testing.
New Malware Loaders Use Call Stack Spoofing, GitHub C2, and .NET Reactor for Stealth
An updated version of a malware loader, known as Hijack Loader, has been discovered with new features aimed at evading detection and maintaining persistence. The
